Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 24Prostatic Neoplasms, Castration-Resistant 4Prostatic Diseases 3Neoplasm Metastasis 3Metastatic Castration-resistant Prostate Cancer 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Male Urogenital Diseases 2Genital Diseases, Male 2Adenocarcinoma 2Urogenital Diseases 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Metastatic 1Non-metastatic Castration-resistant Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1High-Risk Localized Prostate Cancer 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Solid Tumor 1

Interventions

darolutamide 3enzalutamide 2Pluvicto 2talazoparib 1olaparib 1gedatolisib 1apalutamide 1Standard of Care 1Radiotherapy 1Prednisone 1Lutetium-177 1Lutetium 1Docetaxel 1Androgen Antagonists 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Prostatic Diseases × darolutamide × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07103018 2026-03-23

STRIKE-001

K36 Therapeutics, Inc.

Phase 1 Recruiting
144 enrolled
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡